Financials
Financials — What the Numbers Say
1. Financials in One Page
Cigna is a $275B-revenue, ~3% operating-margin, $7-9B free-cash-flow machine trading at a single-digit forward earnings multiple. The 2018 Express Scripts deal turned it from a mid-sized health insurer into a PBM-led colossus where pharmacy services produce ~85% of revenue but only thin pre-tax margins, while the smaller Cigna Healthcare insurance segment carries the regulatory and underwriting risk. The bull case is simple: cash conversion is real, buybacks have shrunk shares 31% since 2018, leverage is manageable at ~2x EBITDA, and FY2026 adjusted-EPS guidance was just raised to at least $30.35 after a clean Q1 beat. The bear case is also simple: GAAP earnings keep getting hit by Medicare-Advantage exit charges, Express Scripts goodwill of $44.9B sits on the balance sheet untouched, and PBM-pricing-reform overhang is keeping the multiple compressed. The single financial metric that matters most right now is the Cigna Healthcare medical care ratio (MCR) — every 100bps move there is roughly $700M of pretax earnings on $70B of insured premium.
Revenue FY2025 ($M)
Operating Margin
Free Cash Flow ($M)
Net Debt / EBITDA
Return on Equity
P/E (GAAP, FY25)
P/E on FY26 Adj. EPS Guide
Dividend Yield
Two earnings numbers exist for Cigna and they tell different stories. GAAP EPS for FY2025 was $22.18; adjusted EPS (which excludes the Medicare-Advantage divestiture loss, intangible amortization from Express Scripts, and special items) was $29.85. The market trades on the adjusted figure — at $282, that's about 9.3x FY26 guided adjusted EPS of $30.35. On GAAP, the multiple is 12.4x trailing. We use both throughout this page and label which is which.
2. Revenue, Margins, and Earnings Power
Cigna's income statement is structurally bi-modal. The 2018 acquisition of Express Scripts (~$67B deal value) tripled revenue from $48.7B in FY2017 to $153.6B in FY2019 and shifted the mix toward pharmacy benefit management. Pharmacy is a pass-through-economics business where reported "revenue" includes the gross cost of drugs flowing through the network, so gross margin compressed from 33.7% to 16.3% overnight, but the dollars of gross profit kept growing. Operating margin runs around 3-4% — typical of PBM-heavy mix; not a sign of weak economics, because pharmacy revenue is closer to a pass-through than a true sale.
The chart shows the structural break in 2019 (Express Scripts consolidation) and a second acceleration in 2024 — that one came from new PBM contract wins (notably Centene's full migration and Health & Welfare gains) layered onto pricing. Revenue grew 11.2% in FY2025, and Q1 FY2026 came in at $68.5B (+10% YoY) with management guiding full-year revenue around $282B. Operating income has barely outgrown revenue since 2019: revenue is up ~79% from FY2019, operating income only ~14%. That tells you the marginal Express Scripts dollar comes in at low single-digit operating margin, and the real operating-income growth has to come from Specialty/Care Services and from underwriting margin in Cigna Healthcare.
Why the margin lines drift down even when dollars grow: revenue includes pass-through drug spend, so each year that PBM scripts grow faster than insurance premiums, headline margins shrink even though pre-tax profit dollars rise. The right way to read 2024–2025 is to look at GAAP net margin (1.5% → 2.2%), which jumped because the FY2024 Medicare-Advantage divestiture charge dropped out and operations underneath kept compounding.
The quarterly trajectory is the clearest evidence the franchise is still compounding: revenue has grown sequentially in every quarter except Q1 25 (when the Medicare-Advantage business officially moved off the books) and Q1 26 (a normal seasonality dip). Operating margin in the trailing four quarters ran 3.0–3.7% — a tight band — and Q1 26's 3.44% is in line with the FY2026 plan. Earnings power is currently improving, not peaking: Q1 FY2026 adjusted EPS of $7.79 grew 16% YoY and beat the $7.35 consensus by 6%.
3. Cash Flow and Earnings Quality
Free cash flow is operating cash flow minus capital expenditure — the cash a business generates after running and maintaining itself. For Cigna it has averaged ~$8.4B per year over 2019-2025 (excluding the $24B Express Scripts deal year, which is acquisition spend, not capex). That is more than reported net income in every year except the post-deal trough, which is the right pattern for a PBM/insurer: customer premiums and pharmacy float arrive before claims and rebates are paid out, generating durable working-capital tailwinds.
The FY2024 spike (FCF was 2.6x net income) is the Medicare-Advantage divestiture distortion: GAAP earnings absorbed a non-cash loss on sale, but the cash kept flowing. FY2023 was the cleanest "true" cash year — $11.8B of operating cash flow against $5.2B of net income, conversion ratio 2.3x — driven by working-capital release as new PBM clients came on. FY2025 normalized to a more sustainable 1.3x (FCF/NI), consistent with a steady-state insurer/PBM.
| Cash-flow line | FY2023 | FY2024 | FY2025 | What it tells you |
|---|---|---|---|---|
| Operating cash flow | $11.8B | $10.4B | $9.6B | Strong but normalizing as MA float runs off |
| Capex | -$2.0B | -$1.5B | -$1.8B | Light: ~0.7% of revenue, pure-play services biz |
| Free cash flow | $9.8B | $8.8B | $7.8B | 3-yr average ~$8.8B, durable |
| Acquisitions | -$0.8B | -$1.2B | -$1.7B | Rising — bolt-ons in specialty/care services |
| Buybacks | -$2.3B | -$7.0B | -$3.6B | Lumpy, tied to MA-divestiture proceeds |
| Dividends paid | -$1.5B | -$1.6B | -$1.6B | Steady ramp; payout still under 30% of FCF |
| Stock-based comp | n/a separately | n/a separately | n/a separately | Not a meaningful FCF distortion (under 1% of revenue) |
Earnings quality verdict: high. GAAP earnings understate cash because of $2.8B/yr of intangible-asset amortization tied to the 2018 Express Scripts goodwill — a non-cash charge that will roll off mechanically. This is also why the gap between adjusted EPS ($29.85) and GAAP EPS ($22.18) is so wide: most of it is amortization plus one-off divestiture charges, not aggressive add-backs.
4. Balance Sheet and Financial Resilience
Cigna's balance sheet is dominated by one decision: the 2018 Express Scripts acquisition added ~$44B of goodwill and ~$39B of intangibles that have barely moved since. Combined, goodwill plus intangibles total $73.5B against $41.9B of book equity — meaning tangible book value is negative by ~$32B. This is normal for a deal-built business; it is not a sign of distress, but it does mean the company can never afford a goodwill impairment.
Net debt has been steady around $23-25B for three years. With trailing EBITDA of $12.0B that's ~2.0x — investment-grade territory and well below the post-deal 2018 peak of 8.0x. Interest coverage (EBIT / interest expense) is 6.5x, comfortable for a steady-cash-flow insurer.
| Liquidity & working-capital snapshot (FY2025) | Value | Read |
|---|---|---|
| Current ratio | 0.85 | Below 1; normal for an insurer because medical claim reserves sit in current liabilities |
| Cash + receivables | $36.4B | Real liquidity buffer |
| Long-term debt | $30.9B | Laddered; weighted-average maturity ~10 yrs based on filings |
| Goodwill / total assets | 28.5% | Concentrated in one acquisition (Express Scripts) |
| Intangibles / total assets | 18.1% | Amortizing $2.8B/yr — adjusted EPS adds this back |
| Tangible book value | -$31.6B | Will stay negative until intangibles fully amortize (~2030) |
| Shareholders' equity | $41.9B | Down from $50.4B in 2020 because buybacks > earnings retained |
Health insurers have a different resilience playbook than ordinary corporates: capital adequacy is regulated at the subsidiary level (RBC ratios), so what matters most isn't the parent's leverage ratio but whether subsidiaries can dividend cash up to the holding company. Per the 10-K, subsidiary dividends to the parent ran ~$5.6B in 2025, easily covering the $1.6B parent dividend and most of the buyback. That funding pipe is the real "balance-sheet flexibility."
The hidden balance-sheet risk is regulatory, not financial. PBM rebate-pass-through legislation (federal and state) could materially compress Express Scripts gross profit and, by extension, Evernorth's pretax earnings. There is no debt covenant or interest-rate trigger that would stress Cigna; the threat is structural margin compression, not solvency.
5. Returns, Reinvestment, and Capital Allocation
Return on invested capital (ROIC) measures pretax operating profit against the equity and debt actually invested in the business. Cigna's ROIC sits around 5-7% — below its weighted cost of capital on the headline figure. That is a function of the giant goodwill base from Express Scripts: if you used tangible invested capital, the underlying ROIC would be far higher. ROE has reset to a more attractive 15.1% in FY2025, helped by a smaller equity base after years of buybacks.
Buybacks are the dominant story. Cumulative buybacks 2017–2025 totaled ~$36B against $34B of cumulative net income. The diluted share count fell from 380.9M at end-FY2018 to 263.5M at end-FY2025 — a 31% reduction in seven years. That is the engine of adjusted EPS growth: even with operating-income growth in the low teens, EPS compounds at high single-digit-plus because the per-share denominator shrinks.
The dividend was non-existent until FY2021 (Cigna paid a token $0.04 then), then ramped to $5.92/share in FY2025 (~22% payout on adjusted EPS, ~28% on FCF). Acquisitions have reaccelerated: $1.7B in FY2025 vs. $0.1B in FY2022 — bolt-ons in specialty pharmacy and Shields Health Solutions (clinical care). Net verdict: management is reinvesting modestly, returning the bulk via buybacks at single-digit forward multiples, and building dividend coverage steadily. That is per-share value compounding, not empire-building.
6. Segment and Unit Economics
Cigna reports two segments. The split is heavily skewed by PBM revenue mechanics:
Note. Segment economics above use the FY2026 management guide (at least $6.9B Evernorth and at least $4.525B Cigna Healthcare adjusted pretax). The JSON data files don't include an explicit segment split, so revenue allocation is approximate based on company disclosures.
The economic asymmetry is the key insight: Evernorth produces ~85% of revenue but only ~62% of pretax profit, while Cigna Healthcare's 15% revenue share generates ~38% of profit. Pretax margin is 3.1% at Evernorth vs. 8.8% at Cigna Healthcare — the inverse of what a cursory glance at the income statement might suggest. The implication for valuation: PBM-pricing reform that takes 100bps off Evernorth pretax margin equals roughly $2.3B of pretax earnings — more than the $4.5B Cigna Healthcare contributes from a 100bps MCR move.
Within Evernorth, the Specialty and Care Services sub-segment is doing the heavy lifting on growth — Q1 FY2026 pretax adjusted earnings grew 20% YoY versus 9% revenue growth for Evernorth overall. That's where rebate compression is least exposed and where biosimilar/specialty-generic substitution lifts margin per script. It is also where bolt-on M&A (Shields, Bright.md) is being directed.
Cigna Healthcare itself has shrunk on purpose: the Medicare-Advantage book and CareAllies were sold to HCSC in early 2025 for ~$3.7B cash, and management announced in Q1 FY2026 it will exit the ACA individual-exchange business by year-end 2026. What remains is large-group commercial (the historical Cigna stronghold) plus international — both higher-MCR-control businesses than Medicare or ACA.
7. Valuation and Market Expectations
Cigna trades for about 9x forward adjusted EPS ($282 / $30.35 FY26 guide) — well below its own 5-year average of ~14x and below where every large managed-care peer except CVS prices today. On EV/EBITDA the multiple is 8.1x, the second-lowest in our peer set after Elevance. P/B at 1.74x is in line with its own 10-year median.
A trailing FCF yield of ~10.7% on a stock generating mid-teens adjusted-EPS growth is unusual. The 2018 anomaly (-29% FCF yield) is the deal year and should be ignored.
Bear / Base / Bull frame (illustrative FY28 algebra)
| Scenario | FY28 Adj. EPS | Multiple | Implied Value | vs. $282 today |
|---|---|---|---|---|
| Bear — PBM reform compresses Express Scripts gross profit, ACA exit hurts Healthcare | ~$32 | 8x | $256 | -9% |
| Base — guide compounds, MCR holds near 84%, buybacks continue | ~$36 | 11x | $396 | +40% |
| Bull — PBM overhang clears, multiple re-rates toward UNH-discount | ~$38 | 13x | $494 | +75% |
Today's price sits at the bear-leaning end of this range. Sell-side targets cluster higher: 12-month published targets run $300 (Wells Fargo) to $410 (Stephens), consensus near $339-361. Recent moves have been mixed — Goldman cut $370→$330 after FY25 results, JP Morgan $428→$375 — but every covering analyst remains above today's $282.
The valuation gap exists for a reason. Investors are not arguing about whether 2026 numbers will be hit — Q1 already validated them. They are pricing in a structurally lower long-term margin if PBM rebate-pass-through becomes federal law. That is a genuine risk, not a "market-mispricing" call.
8. Peer Financial Comparison
Three things stand out from the peer table:
Cigna trades at the lowest GAAP P/E among the profitable peers (12.4x vs. UNH 25.0x, HUM 26.0x, CVS 57.1x; only ELV is comparable at 13.9x). On EV/EBITDA the gap is narrower but still meaningful: 8.1x vs. UNH 13.2x.
Cigna's ROE (15.1%) is in the middle of the pack — better than UNH (12.5%) and HUM (7.0%), worse than ELV (13.3%) on a tighter equity base. The market is not paying for Cigna's per-share economics.
Cigna runs more leverage than the average managed-care peer (1.99x ND/EBITDA vs. UNH and HUM at 0x net cash, ELV at -0.6x net cash). That is partly a relic of the Express Scripts financing and partly a sign that buybacks have run hotter than retained earnings.
The comparison most relevant to the multiple debate is CI vs. UNH: similar PBM and managed-care exposure, similar ROIC, similar revenue growth in 2025 — but UNH trades at a 100% premium on P/E. Some of that premium is justified (UNH's Optum Health adds a higher-margin care-delivery business Cigna doesn't have at scale yet, and UNH has zero net debt) but most of it is regulatory: UNH's Medicare-Advantage scale gives it more political vulnerability and more pricing power, and the market currently rewards the latter.
9. What to Watch in the Financials
What the financials confirm and contradict
The numbers confirm: Cigna is a high-quality cash machine. FCF has averaged $8.4B/yr post-deal, conversion to net income is consistently above 1x, leverage is steady at ~2x EBITDA, ROE is in the mid-teens, and a 31% share-count reduction since 2018 is doing the heavy lifting on per-share growth. Underlying operating-segment profit growth is healthy — Specialty/Care +20%, Cigna Healthcare +18% in Q1 FY2026.
The numbers sit in tension with the price. At 9x forward adjusted EPS, ~10.7% trailing FCF yield, and a 100% discount to UNH's GAAP P/E for similar ROIC and revenue growth, the multiple is consistent with regulatory damage that has not yet appeared in any segment line item. There is no balance-sheet stress, no margin collapse in segment reporting, and no consensus-EPS deterioration — but the FY26 Evernorth guide is below FY25, and the legislative dates are real.
The first financial metric to watch is the FY2026 Cigna Healthcare MCR. Guide is 83.7-84.7% for the full year; Q1 came in at 79.8%, but Q2 typically prints higher. Inside that band, FY26 adjusted EPS lands at or above $30.35 and buyback math takes diluted share count below 260M — an algebraic boost to FY27 earnings power before any operating tailwind. Above 84.7%, the bear scenario becomes the base case and the depressed multiple is consistent with the new evidence.